<DOC>
	<DOCNO>NCT00546871</DOCNO>
	<brief_summary>The purpose study evaluate tolerability IGIV , 10 % give subcutaneously pharmacokinetics immunoglobulin G ( IgG ) follow subcutaneous ( SC ) treatment IGIV , 10 % subject primary immunodeficiency ( PID ) disorder .</brief_summary>
	<brief_title>Comparison Intravenous Subcutaneous Administration IGIV , 10 % Primary Immunodeficiency ( PID ) Subjects</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Written inform consent obtain either subject subject 's legally acceptable representative prior studyrelated procedure study product administration Diagnosis PID disorder define World Health Organization criterion ( IUIS Scientific Committee , Primary immunodeficiency disease . Report IUIS Scientific Committee . Clin Exp Immunol . 1999 ) subject receive regular regimen IV immunoglobulin infusion every 21 ± 3 day 28 ± 3 day regular SC immunoglobulin treatment 1 2 week interval period least 3 month prestudy dose 300800 mg/kg BW/4 week Subjects age 2 year old Subjects serum trough level IgG &gt; 4.5 g/L last documented determination A negative serum pregnancy test female subject childbearing potential Female subject childbearing potential agree practice birth control measure duration study Subjects positive enrollment one following : Hepatitis B surface antigen ( HBsAg ) , PCR hepatitis C virus ( HCV ) , PCR human immunodeficiency virus ( HIV ) Type 1 Subjects level alanine amino transferase ( ALT ) aspartate amino transferase ( AST ) &gt; 2.5 time upper limit normal test laboratory Subjects neutropenia ( define absolute neutrophil count [ ANC ] &lt; = 500/mm3 ) Subjects serum creatinine level great 1.5 time upper limit normal age gender Subjects malignancy adequately treat basal cell squamous cell carcinoma skin carcinoma situ cervix Subjects history thrombotic episode ( deep vein thrombosis , myocardial infarction , cerebrovascular accident ) Subjects abnormal protein loss ( protein lose enteropathy , nephritic syndrome , severe lung disease ) Subjects anemia would preclude phlebotomy laboratory study Subjects receive blood blood product IGIV , SC immunoglobulin , immune serum globulin ( ISG ) preparation , albumin within 6 month prior study enrollment Subjects ongoing history hypersensitivity persistent reaction ( urticaria , breathe difficulty , severe hypotension , anaphylaxis ) follow IGIV , SC immunoglobulin and/or ISG infusion Subjects IgA deficiency know anti IgA antibody Subjects receive antibiotic therapy treatment infection within 7 day prior enrollment Subjects participate another clinical study involve investigational product device within 28 day prior study enrollment Subjects bleeding disorder anticoagulation therapy</criteria>
	<gender>All</gender>
	<minimum_age>24 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>